



## Manufacturers' Forum **ANNOUNCEMENT** NorthStar HealthCare Consulting Georgia Department of Community Health

On behalf of the Georgia Department of Community Health (DCH) and in service to the Georgia Medicaid Fee-for-Service (FFS) Drug Utilization Review Board (DURB), NorthStar HealthCare Consulting (NHC), in conjunction with OptumRx, announces the Manufacturers' Forum for the July 2024 DUR Board meeting.

**Appointments: *The Manufacturers' Forum is by appointment only and will be conducted virtually for the July 2024 DUR Board meeting.*** Appointments may be requested *after* the Drugs Under Review document is posted to the DCH website at <https://dch.georgia.gov/providers/provider-types/pharmacy/drug-utilization-review-board>. ***Only manufacturers with drugs up for review at the upcoming DURB meeting will be granted appointments at this Forum.*** All requests for appointments must be made in writing to [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com) and include the drug name. **New drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

### **Guidelines for Participation:**

- Individual manufacturer participation shall be limited to one 60-minute time segment per Forum. The presentation shall be limited to approximately 40 minutes with 20 minutes for questions and answers.
- An electronic **one-page** summary (front only, font 10, not including references) of each drug presentation, **factually based**, in a stand-alone, user-friendly document should be provided one week prior to the presentation via email to [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com). Please include a pronunciation guide of the drug's brand and generic names. The one-page summary may be provided to the DURB members.

### **Helpful Information for Manufacturers with non-DURB Drugs:**

- Manufacturers with *new drugs* that are *not* under review at the current DURB meeting are requested to wait until their drug is under review at a DURB meeting to request Forum participation.
- Manufacturers with *new drugs* that have *orphan designation* are highly encouraged to share any noteworthy information regarding their drug for review by DCH and NHC electronically. Please follow the one-page summary format described above and send to [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com).
- Manufacturers seeking appointments for drugs that are currently listed on the Preferred Drug List (PDL) and/or the Providers' Administered Drug List (PADL) will be granted appointments on an *ad hoc* basis at DCH/NHC's discretion. Regardless of whether an appointment is granted, all manufacturers are encouraged to send relevant, pertinent clinical information electronically to [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com) for our review. Please follow the one-page summary format described above.

### **Comments and Inquiries:**

- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **Preferred Drug List, Prior Authorization Criteria, Manufacturers' Forum or DURB** should submit these in writing to [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com).
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **claims processing** or **drug benefit plan design** should submit these in writing to [Tami.Sweat@optum.com](mailto:Tami.Sweat@optum.com).
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **supplemental rebates** should submit these in writing to [Georgia-DURB@magellanhealth.com](mailto:Georgia-DURB@magellanhealth.com).